Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma-Reference-Cited by-同舟云学术

Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma

Published:2023-01 Issue: Volume:87 Page:104420
ISSN:2352-3964
Container-title:eBioMedicine
language:en
Short-container-title:eBioMedicine

Author:

Wen Tingyu,Sun Guangyi,Jiang Wenxin,He Xiaohui,Shi Yuankai,Ma Fei,Liu Peng^ORCID

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference43 articles.

1. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification;Sun;Am J Clin Pathol,2012

2. Extranodal NK/T cell lymphoma, Nasal Type (ENKTL-NT): an update on epidemiology, clinical presentation, and Natural History in North American and European cases;Haverkos;Curr Hematol Malig Rep,2016

3. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group;Kwong;Blood,2012

4. Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study;Yang;Leukemia,2020

5. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes;Panjwani;Hum Pathol,2018

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer/T cell lymphoma;Chinese Medical Journal;2024-08-23

2. Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study;Signal Transduction and Targeted Therapy;2024-05-17

3. Combination of chidamide and PD-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy;International Immunopharmacology;2024-05

4. How can we establish animal models of HIV‐associated lymphoma?;Animal Models and Experimental Medicine;2024-04-03

5. HDAC-targeting epigenetic modulators for cancer immunotherapy;European Journal of Medicinal Chemistry;2024-02